Invion Ltd. (AU:IVX) has released an update.
Invion Limited has issued 33.3 million new shares at $0.003 each, under a special provision avoiding the usual investor disclosure, while complying with all necessary regulatory requirements. The company is also engaged in early-stage talks to expand the license rights for its Photosoft™ technology, used in cancer treatment, with current licensor RMW Cho Group Limited, although the outcome remains uncertain. Invion continues to advance its role in developing Photosoft™ as an innovative cancer treatment and holds the license for Australia and New Zealand.
For further insights into AU:IVX stock, check out TipRanks’ Stock Analysis page.
